News

Dazodalibep Eases Moderate-to-high Disease Activity in Sjögren’s Patients: Trial Data

The investigational therapy dazodalibep markedly eased disease activity in people with Sjögren’s syndrome with moderate-to-high systemic disease activity, meeting the primary goal of a Phase 2 trial. Ahead of expectations, the therapy’s developer, Horizon Therapeutics, plans to work with the U.S. Food and Drug Administration (FDA) to design…

Memory Problems Common in Sjögren’s, Linked to Global Cognitive Impairment

Memory complaints in people with primary Sjögren’s syndrome are linked to global cognitive impairment — problems affecting not only memory but also other mental faculties, according to data from a small study. While researchers noted that “associated psychiatric and sleep disorders greatly interfere” with cognition in Sjögren’s patients, they…